Literature DB >> 29438042

In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease.

Gregory S Day1, Brian A Gordon2, Richard J Perrin2, Nigel J Cairns2, Helen Beaumont2, Katherine Schwetye2, Cole Ferguson2, Namita Sinha2, Robert Bucelli2, Erik S Musiek2, Nupur Ghoshal2, Maria R Ponisio2, Benjamin Vincent2, Shruti Mishra2, Kelley Jackson2, John C Morris2, Tammie L S Benzinger2, Beau M Ances2.   

Abstract

OBJECTIVE: To determine whether specific patterns of [18F]-AV-1451 tau-PET retention are observed in patients with autopsy-proven sporadic Creutzfeldt-Jakob disease (CJD).
METHODS: In vivo [18F]-AV-1451 PET neuroimaging was performed in 5 patients with sporadic CJD (median age, 66 years [63-74]), and results were compared to cognitively normal (CN) persons (n = 44; median age, 68 years [63-74]) and to participants with very mild Alzheimer disease (AD) dementia (n = 8; median age, 77 years [63-90]). Autopsy was completed in all patients with CJD, confirming the clinical diagnosis and permitting characterization of AD neuropathologic change (ADNC).
RESULTS: All patients with CJD presented with rapidly progressive dementia, typical magnetic resonance brain imaging changes, and elevated CSF total tau (median = 6,519; range = 1,528-13,240 pg/mL). Death occurred within 9 months of symptom onset, with a median 1 month (0.2-3.3) interval from [18F]-AV-1451 PET to autopsy. No unique pattern of [18F]-AV-1451 retention was observed on visual inspection. Summary standardized uptake value ratios in patients with CJD (1.17, 1.08-1.36) were indistinguishable from CN persons (1.14, 0.84-1.54; p = 0.6), and well below those of participants with AD (2.23, 1.60-3.04; p ≤ 0.01). [18F]-AV-1451 retention in patients with CJD and CN persons was similar in brain areas frequently affected in AD and CJD. Neuropathologic analysis confirmed the clinical diagnosis in all patients with CJD. Four patients with CJD also had low-level ADNC (A1B1C0); one patient had intermediate-level ADNC (A2B2C1/2).
CONCLUSION: Increased [18F]-AV-1451 retention was not observed in patients with rapidly progressive dementia due to sporadic CJD. The [18F]-AV-1451 PET tracer maintains good specificity for paired helical tau filaments associated with AD dementia.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29438042      PMCID: PMC5863493          DOI: 10.1212/WNL.0000000000005064

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

1.  Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry.

Authors:  Tobias Skillbäck; Christoffer Rosén; Fredrik Asztely; Niklas Mattsson; Kaj Blennow; Henrik Zetterberg
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

2.  A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease.

Authors:  Clive Hamlin; Gianfranco Puoti; Sally Berri; Elliott Sting; Carrie Harris; Mark Cohen; Charles Spear; Alberto Bizzi; Sara M Debanne; Douglas Y Rowland
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

3.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

Authors:  Adam J Schwarz; Peng Yu; Bradley B Miller; Sergey Shcherbinin; James Dickson; Michael Navitsky; Abhinay D Joshi; Michael D Devous; Mark S Mintun
Journal:  Brain       Date:  2016-03-02       Impact factor: 13.501

4.  Rapidly progressive Alzheimer's disease: a multicenter update.

Authors:  Christian Schmidt; Stephane Haïk; Katsuya Satoh; Alberto Rábano; Pablo Martinez-Martin; Sigrun Roeber; Jean-Philippe Brandel; Miguel Calero-Lara; Jesús de Pedro-Cuesta; Jean-Louis Laplanche; Jean-Jaques Hauw; Hans Kretzschmar; Inga Zerr
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

5.  CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease.

Authors:  P Sanchez-Juan; A Green; A Ladogana; N Cuadrado-Corrales; R Sáanchez-Valle; E Mitrováa; K Stoeck; T Sklaviadis; J Kulczycki; K Hess; M Bodemer; D Slivarichová; A Saiz; M Calero; L Ingrosso; R Knight; A C J W Janssens; C M van Duijn; I Zerr
Journal:  Neurology       Date:  2006-08-22       Impact factor: 9.910

6.  Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.

Authors:  M Riemenschneider; S Wagenpfeil; H Vanderstichele; M Otto; J Wiltfang; H Kretzschmar; E Vanmechelen; H Förstl; A Kurz
Journal:  Mol Psychiatry       Date:  2003-03       Impact factor: 15.992

7.  Partial volume correction in quantitative amyloid imaging.

Authors:  Yi Su; Tyler M Blazey; Abraham Z Snyder; Marcus E Raichle; Daniel S Marcus; Beau M Ances; Randall J Bateman; Nigel J Cairns; Patricia Aldea; Lisa Cash; Jon J Christensen; Karl Friedrichsen; Russ C Hornbeck; Angela M Farrar; Christopher J Owen; Richard Mayeux; Adam M Brickman; William Klunk; Julie C Price; Paul M Thompson; Bernadino Ghetti; Andrew J Saykin; Reisa A Sperling; Keith A Johnson; Peter R Schofield; Virginia Buckles; John C Morris; Tammie L S Benzinger
Journal:  Neuroimage       Date:  2014-12-05       Impact factor: 6.556

8.  In vivo retention of 18F-AV-1451 in corticobasal syndrome.

Authors:  Ruben Smith; Michael Schöll; Håkan Widner; Danielle van Westen; Per Svenningsson; Douglas Hägerström; Tomas Ohlsson; Jonas Jögi; Christer Nilsson; Oskar Hansson
Journal:  Neurology       Date:  2017-07-28       Impact factor: 9.910

9.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.

Authors:  Matthew R Brier; Brian Gordon; Karl Friedrichsen; John McCarthy; Ari Stern; Jon Christensen; Christopher Owen; Patricia Aldea; Yi Su; Jason Hassenstab; Nigel J Cairns; David M Holtzman; Anne M Fagan; John C Morris; Tammie L S Benzinger; Beau M Ances
Journal:  Sci Transl Med       Date:  2016-05-11       Impact factor: 17.956

10.  Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.

Authors:  Stephen N Gomperts; Joseph J Locascio; Sara J Makaretz; Aaron Schultz; Christina Caso; Neil Vasdev; Reisa Sperling; John H Growdon; Bradford C Dickerson; Keith Johnson
Journal:  JAMA Neurol       Date:  2016-11-01       Impact factor: 18.302

View more
  14 in total

1.  Structural signature of sporadic Creutzfeldt-Jakob disease.

Authors:  J Navid; G S Day; J Strain; R J Perrin; R C Bucelli; A Dincer; J K Wisch; D Soleimani-Meigooni; J C Morris; T L S Benzinger; B M Ances
Journal:  Eur J Neurol       Date:  2019-03-25       Impact factor: 6.089

Review 2.  Rapidly Progressive Dementia.

Authors:  Gregory S Day
Journal:  Continuum (Minneap Minn)       Date:  2022-06-01

3.  Tau-positron emission tomography correlates with neuropathology findings.

Authors:  Val J Lowe; Emily S Lundt; Sabrina M Albertson; Hoon-Ki Min; Ping Fang; Scott A Przybelski; Matthew L Senjem; Christopher G Schwarz; Kejal Kantarci; Bradley Boeve; David T Jones; R Ross Reichard; Jessica F Tranovich; Fadi S Hanna Al-Shaikh; David S Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Melissa E Murray
Journal:  Alzheimers Dement       Date:  2020-01-04       Impact factor: 21.566

4.  Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions.

Authors:  Gregory S Day; Erik S Musiek; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Oct-Dec       Impact factor: 2.703

5.  Combined findings of FDG-PET and arterial spin labeling in sporadic Creutzfeldt-Jakob disease.

Authors:  Junliang Yuan; Shuangkun Wang; Wenli Hu
Journal:  Prion       Date:  2018-10-09       Impact factor: 3.931

6.  Author response: In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease.

Authors:  Gregory S Day; Brian A Gordon; Richard J Perrin; Beau M Ances
Journal:  Neurology       Date:  2019-01-15       Impact factor: 9.910

7.  Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient.

Authors:  Gregory S Day; Brian A Gordon; Robert C Bucelli; Richard J Perrin; A Sebastian Lopez-Chiriboga; Beau M Ances
Journal:  J Neuroimmunol       Date:  2021-01-07       Impact factor: 3.478

Review 8.  Multiparametric magnetic resonance imaging and positron emission tomography findings in neurodegenerative diseases: Current status and future directions.

Authors:  Neetu Soni; Manish Ora; Girish Bathla; Chandana Nagaraj; Laura L Boles Ponto; Michael M Graham; Jitender Saini; Yusuf Menda
Journal:  Neuroradiol J       Date:  2021-03-05

9.  β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns.

Authors:  Chenyang Jiang; Qingyong Wang; Siwei Xie; Zhicheng Chen; Liping Fu; Qiyu Peng; Ying Liang; Hongbo Guo; Tengfei Guo
Journal:  Brain Commun       Date:  2022-03-31

10.  THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report.

Authors:  Hee Jin Kim; Hanna Cho; Seongbeom Park; Hyemin Jang; Young Hoon Ryu; Jae Yong Choi; Seung Hwan Moon; Seung Jun Oh; Minyoung Oh; Duk L Na; Chul Hyoung Lyoo; Eun-Joo Kim; William W Seeley; Jae Seung Kim; Kyung Chan Choi; Sang Won Seo
Journal:  BMC Neurol       Date:  2019-08-29       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.